Tag Archives: Opko Health

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Synthetic Biologics (SYN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opko Health (OPK – Research Report) and Synthetic Biologics (SYN – Research Report) with bullish sentiments. Opko Health (OPK) Barrington analyst Michael

Analysts Are Bullish on Top Healthcare Stocks: Opko Health (OPK), TherapeuticsMD (TXMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opko Health (OPK – Research Report) and TherapeuticsMD (TXMD – Research Report) with bullish sentiments. Opko Health (OPK) Barrington analyst Michael Petusky

Barrington Keeps Their Buy Rating on Opko Health (OPK)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPK – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $1.40, close to its 52-week low of

A Director at Opko Health (NASDAQ: OPK) is Buying Shares

Today, a Director at Opko Health (OPK – Research Report), Richard Pfenniger, bought shares of OPK for $36K. This recent transaction increases Richard Pfenniger’s holding in the company by 10% to a total of $448.3K. In addition to Richard Pfenniger,

Barrington Reaffirms Their Buy Rating on Opko Health (OPK)

Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (OPK – Research Report) today and set a price target of $4. The company’s shares closed last Monday at $2.15, close to its 52-week low of $1.73. Petusky wrote:

The Executive VP-Administration of Opko Health (NASDAQ: OPK) is Buying Shares

Today, the Executive VP-Administration of Opko Health (OPK – Research Report), Steven D. Rubin, bought shares of OPK for $21.44K. In addition to Steven D. Rubin, 13 other OPK executives reported Buy trades in the last month. See today’s analyst